INTRODUCTION {#s1}
============

Primary breast lymphoma (PBL) is a rare form of extra-nodal lymphoid neoplasm. It represents 1% of non-Hodgkin's lymphomas (NHL) and 2,2% of extra-nodal lymphomas. PBL usually presents as a painless mass of progressive growth with or without ipsilateral axillary lymph nodes and more than 96% of the cases affect to women \[[@R1]--[@R3]\]. It was first described in 1972 by Wiseman and Liao \[[@R4]\], who defined diagnostic criteria, which would be later modified by Hugh et al \[[@R5]\], defining the PBL as the infiltration of breast tissue by lymphoma with or without regional lymph node in patients without a history of prior nodal or extra-nodal lymphoma and systemic disease at the time of diagnosis. More than 95% of the cases correspond to B-type NHL and the most common histopathological type is diffuse large B-cell lymphoma (DLBCL), which represents 60--80% of all the cases. Other less frequent subtypes include follicular lymphoma and marginal zone lymphoma MALT-type \[[@R5]--[@R6]\]. The treatment of primary breast DLBCL (PB-DLBCL) is based on regimes like R-CHOP (Cyclophosphamide, Doxorrubicin, Vincristine, Prednisone and Rituximab) or similar treatments. In the Rituximab era an overall survival (OS) at 5 years may reach 87% \[[@R6]--[@R9]\]. The genetic alterations of PB-DLBCL have not been previously analyzed, except for the study from Taniguchi et al regarding MYD88 and CD79B \[[@R10]\], partly due to the infrequency of this presentation and the difficulty in obtaining sufficient tumor tissue to perform molecular analysis. Our objective is, therefore, to contribute to the knowledge on the mutational landscape of PB-DLBCL.

RESULTS {#s2}
=======

The study population consists of 17 patients, all women, with PB-DLBCL diagnosed between 1993 and 2016 in different medical centers in Spain. The average age of diagnosis was 66 years (range, 29--84) (Table [1](#T1){ref-type="table"}). In nine cases, the left breast was involved; in 7 cases the right one and both in one case. Seventy-point-five percent of the patients presented with stage IE and 29.5% stage IIE. All patients received immunochemotherapy (R-CHOP or similar), except one who was treated with CHOP. All the patients achieved complete response (CR) (Table1). There were 2 relapses in the contralateral breast, both treated with second-line regimens that achieved CR. From one of these patients we confirmed the diagnosis and acquired the relapsing samples. There were also 1 systemic nodal relapse and 1 brain relapse, both of which died from disease progression. The median progression free survival (PFS) was 7 years and the median OS was 16 years.

###### Clinical data of PB-DLBCL patients

  Patient   Age   Laterality   Nodal involvement   Stage   IPI   Chemo-therapy   Cycles   Radio-therapy   Response to treatment   Relapse                Treatment      Time to progression   Response to treatment
  --------- ----- ------------ ------------------- ------- ----- --------------- -------- --------------- ----------------------- ---------------------- -------------- --------------------- -----------------------
  01        84    Left         No                  IE      2     R-CVP           5        Yes             CR                                                                                  
  02        78    Right        No                  IE      1     R-CHOP          4        No              CR                                                                                  
  03        74    Left         No                  IE      2     R-CHOP          4        No              CR                                                                                  
  04        40    Right        Yes                 IIE     0     R-CHOP          4        Yes             CR                                                                                  
  05        60    Left         No                  IE      1     R-CHOP          8        No              CR                                                                                  
  06        29    Right        No                  IE      0     R-CHOP          6        No              CR                                                                                  
  07        78    Bilateral    Yes                 IIE     1     R-CHOP          6        No              CR                                                                                  
  08        73    Left         No                  IE      2     CHOP            6        No              CR                                                                                  
  09        75    Left         No                  IE      1     R-CHOP          4        No              CR                                                                                  
  10        79    Left         No                  IE      2     R-CHOP          6        No              CR                                                                                  
  11        83    Right        Yes                 IIE     2     R-MVP           6        No              CR                      Nodal                  No treatment   7 m                   Progression
  12        70    Right        No                  IE      1     R-CHOP          6        No              CR                      Contralateral breast   R-ESHAP        80 m                  CR
  13        79    Left         No                  IE      1     R-CHOP          4        Yes             CR                                                                                  
  14        62    Right        No                  IE      1     R-CHOP          4        Yes             CR                      Brain                  Methotrexate   23 m                  Progression
  15        70    Left         No                  IE      2     R-CHOP          6        No              CR                                                                                  
  16        46    Left         Yes                 IIE     ND    R-CHOP          6        No              CR                                                                                  
  17        42    Right        Yes                 IIE     ND    R-CHOP          6        Yes             CR                      Contralateral breast   R-COMP         157 m                 CR

Abbreviations: R-CVP: Rituximab, Cyclophosphamide, Vincristine, Prednisone; R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; R-MVP: Rituximab, Methotrexate, Vincristine, Procarbazine; R-COMP: Rituximab, Cyclophosphamide, Myocet, Prednisone; R-ESHAP: Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin; CR: Complete response; ND: No data; m: months

Forty-four-point-four percent of the analyzed samples were classified, according to Hans's algorithm (see Materials and Methods), as germinal center B-cell (GCB) DLBCL, 33.3% as non-GCB, while 16.6% were unclassified (Table [2](#T2){ref-type="table"}). The proliferation index, determined by Ki-67 expression, was higher than or equal to 80% in 16/18 samples; only samples from patients 2 and 3 showed values of Ki67 expression of 57 and 70%, respectively.

###### Immunohistochemical results and cell of origin (COO) determined according to Hans's algorithm in PB-DLBCL

  SAMPLE   CD10   CD20   BCL6   BCL2   MUM1   Ki67   COO
  -------- ------ ------ ------ ------ ------ ------ ---------
  01       \+     \+     \+     \+     ND     96%    GCB
  03       --     \+     \+     \+     --     70%    GCB
  04       \+     \+     \+     --     --     80%    GCB
  05       \+     \+     \+     \+     ND     80%    GCB
  06       ND     \+     \+     \+     --     80%    GCB
  07       ND     \+     \+     \+     --     90%    GCB
  08       --     \+     \+     \+     --     80%    GCB
  09       --     \+     \+     \+     --     85%    GCB
  02       --     \+     --     \+     ND     59%    Non-GCB
  10       --     \+     \+     \+     \+     80%    Non-GCB
  11       --     \+     --     --     \+     100%   Non-GCB
  12a      ND     \+     ND     ND     ND     98%    ND
  12b      --     \+     \+     \+     \+     98%    Non-GCB
  15       ND     \+     \+     \+     \+     80%    Non-GCB
  16       --     \+     \+     \+     \+     80%    Non-GCB
  17       --     \+     \+     \+     \+     80%    Non-GCB
  13       ND     \+     ND     ND     ND     90%    ND
  14       --     \+     \+     \+     ND     100%   ND

GCB: germinal center B-cell; non-GCB: non-germinal center B-cell, ND: No data.

We designed a targeted sequencing panel for aggressive B-cell lymphomas including 38 recurrently mutated genes described in the literature ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) \[[@R11]--[@R14]\]. TruSeq^®^ Custom Amplicon Low Input Library for dual-strand sequencing (Illumina Inc. San Diego CA, USA) was used. Median coverage for the amplicons for pool A was 379× (50--1098×) and pool B was 426× (30--2149×). After sequencing 18 samples from the 17 patients included in the study, we found a total of 52 non-synonimous and 21 synonimous mutations; at least 1 mutated gene (taking into account exclusively missense, nonsense, frameshift and splicing mutations) were found in 15 of them. Samples 5, 12a and 13 had the highest numbers of mutated genes, with 4, 6 and 7 respectively (Figure [1](#F1){ref-type="fig"}, Table [3](#T3){ref-type="table"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Some cases had more than one mutation per gene. We identified mutations in 14 of the 38 selected genes (*PIM1, MYD88, KMT2D, CARD11, CD79B, PRDM1, ATM, BRAF, CREBBP, TNFAIP3, CCND3, PLCG2, TCF3* and *STAT3*) (Figure [1](#F1){ref-type="fig"}, Table [3](#T3){ref-type="table"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The recurrently mutated genes were *PIM1* (in 9/18 samples; 50%), *MYD88* (7/18, 39%), *CD79B, PRDM1* and *CARD11* (3/18; 17%), *KMT2D, TNFAIP3* and *CREBBP* (2/18; 11%) (Figure [1](#F1){ref-type="fig"}, Table [3](#T3){ref-type="table"} and [Supplementary Tables 2 and 3)](#SD1){ref-type="supplementary-material"}.

![Frequencies and distribution of gene mutations in PB-DLBCL, and cell of origin (CCO)\
A total of 18 PB-DLBCL samples were subjected to targeted massive paralleled sequencing for 38 frequently mutated genes in DLBCL. Columns represent samples and the rows represent the mutated genes. Colored box (red) indicates at least 1 mutation in the given gene. The bottom row shows the COO for each sample (blue: GCB; green: non-GCB; grey: no data). Patient number 12 had two samples (12a, taken at the time of diagnosis, and 12b at the time of relapse). The horizontal bars at the right of the figure represents percentage of mutated samples.](oncotarget-08-102888-g001){#F1}

###### Non-synonymous somatic variants identified in PB-DLBCL samples

  Sample        Position         Ref/Alt   Gene                      Function   Exon               CDS change   aa change
  ------------- ---------------- --------- ------------------------- ---------- ------------------ ------------ -----------
  1             6:37140780       G/A       PIM1                      missense   exon5              c.G616A      p.V206M
  6:106536093   C/CTCCA          PRDM1     frameshift_variant        exon2      c.60_61insCCGGCT   p.Ser21fs    
  3             16:3820828       G/A       CREBBP                    missense   exon14             c.C2623T     p.P875S
  5             17:62006799      A/G       CD79B                     missense   exon5              c.T586C      p.Y196H
  3:38182641    T/C              MYD88     missense                  exon5      c.T794C            p.L265P      
  6:37138405    C/A              PIM1      missense                  exon1      c.C54A             p.N18K       
  6:37138427    G/A              PIM1      missense                  exon1      c.G76A             p.A26T       
  6:37139097    G/A              PIM1      missense                  exon4      c.G437A            p.S146N      
  6:37139180    C/T              PIM1      missense                  exon4      c.C520T            p.L174F      
  6:138200190   C/A              TNFAIP3   stopgain                  exon7      c.C1608A           p.C536X      
  6             12:49420433      G/A       KMT2D                     missense   exon48             c.C15316T    p.R5106C
  3:38182641    T/C              MYD88     missense                  exon5      c.T794C            p.L265P      
  7             7:2978320        C/T       CARD11                    missense   exon7              c.G1010A     p.R337Q
  3:38182641    T/C              MYD88     missense                  exon5      c.T794C            p.L265P      
  8             7:2987341        G/A       CARD11                    missense   exon3              c.C88T       p.R30W
  6:37139033    C/T              PIM1      missense                  exon4      c.C373T            p.P125S      
  9             17:62006797      G/C       CD79B                     stopgain   exon5              c.C588G      p.Y196X
  6:106536235   G/A              PRDM1     missense                  exon2      c.G202A            p.D68N       
  10            6:41903731       G/A       CCND3                     stopgain   exon5              c.C826T      p.Q276X
  6:138200458   C/CT             TNFAIP3   frameshift_variant        exon7      c.1876_1877insT    p.Leu626fs   
  11            11:108172446     G/A       ATM                       stopgain   exon35             c.G5249A     p.W1750X
  12a           11:108119789     C/T       ATM                       missense   exon9              c.C1195T     p.H399Y
  7:140482915   G/A              BRAF      missense                  exon10     c.C1220T           p.P407L      
  16:3788614    G/A              CREBBP    missense                  exon26     c.C4340T           p.T1447I     
  3:38182641    T/C              MYD88     missense                  exon5      c.T794C            p.L265P      
  6:37138401    G/A              PIM1      missense                  exon1      c.G50A             p.C17Y       
  6:37139039    C/T              PIM1      stopgain                  exon4      c.C379T            p.Q127X      
  17:40476822   G/A              STAT3     stopgain                  exon17     c.C1507T           p.Q503X      
  12b           3:38182641       T/C       MYD88                     missense   exon5              c.T794C      p.L265P
  6:37138625    C/G              PIM1      stopgain                  exon2      c.C159G            p.Y53X       
  6:37138946    G/C              PIM1      missense                  exon4      c.G286C            p.V96L       
  6:37139210    C/T              PIM1      missense                  exon4      c.C550T            p.L184F      
  13            7:2977612        A/T       CARD11                    missense   exon8              c.T1072A     p.C358S
  17:62006647   A/G              CD79B     missense                  exon6      c.T629C            p.I210T      
  17:62006680   A/T              CD79B     missense                  exon6      c.T596A            p.L199Q      
  3:38182641    T/C              MYD88     missense                  exon5      c.T794C            p.L265P      
  6:37138808    G/T              PIM1      splice_donor_variant                                                 
  6:37138597    TGGGCAGCGGCG/T   PIM1      frameshift_variant        exon2      c.132del11         p.Leu44fs    
  6:37139029    CGAGCCGGT/C      PIM1      frameshift_variant        exon4      c.370delGAGCCGGT   p.Glu124fs   
  6:37139210    C/T              PIM1      missense                  exon4      c.C550T            p.L184F      
  16:81929465   C/T              PLCG2     missense                  exon13     c.C1126T           p.R376W      
  6:106536324   G/C              PRDM1     missense                  exon2      c.G291C            p.E97D       
  19:1622393    C/T              TCF3      missense                  exon9      c.G571A            p.E191K      
  14            12:49440169      C/T       KMT2D                     missense   exon16             c.G4457A     p.G1486D
  12:49433401   C/T              KMT2D     splice_acceptor_variant   intron31                                   
  6:37138424    C/G              PIM1      missense                  exon1      c.C73G             p.L25V       
  15            6:37138769       C/T       PIM1                      missense   exon3              c.C202T      p.H68Y
  6:37138976    C/T              PIM1      missense                  exon4      c.C316T            p.L106F      
  16            3:38182641       T/C       MYD88                     missense   exon5              c.T794C      p.L265P
  6:37138354    G/A              PIM1      start_lost                exon1      c.G3A              p.M1I        
  6:37138916    G/C              PIM1      missense                  exon4      c.G256C            p.V86L       
  6:37139204    C/T              PIM1      missense                  exon4      c.C544T            p.L182F      

Ref, reference base; Alt, altered base; CDS, coding sequence; aa, aminoacid.

The high frequency of *PIM1* mutations is one of the most relevant findings of this study. We have identified 21 non-synonymous and 20 synonymous *PIM1* mutations in 9 samples. Many of the non-synonymous mutations of *PIM1* affected mainly to the serine/threonine dual specificity protein kinase, catalytic domain (aa 38--290). *MYD88* is the second most frequently mutated gene in this series, and all the cases showed the L265P mutation. The four mutations found in *CD79B* (one case showing 2 mutations) were located in exons 5 and 6 affecting the ITAM domain (aa 185--213), two of them affecting the tyrosine Y196 (Table [3](#T3){ref-type="table"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

For one patient (patient number 12), who was diagnosed of PBL on the right breast in 2010 and then of a contralateral relapse in 2015, we sequenced both samples and found that they only shared the L265P-MYD88 mutation and a synonymous one in *PIM1* (Table [3](#T3){ref-type="table"} and [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The rest of the mutated genes (*CREBBP, ATM, BRAF* and *STAT3*) and most mutations in *PIM1,* were different. This may suggest that both tumors share a common precursor, but they followed completely different paths of evolution, giving rise to different lymphomas.

DISCUSSION {#s3}
==========

In the last twenty years multiple PBL retrospective clinical studies were published including one randomized clinical trial \[[@R1]--[@R10], [@R15]--[@R16]\]. However, only two molecular studies, both in oriental population (China and Japan), has been reported \[[@R10], [@R17]\]. The clinical profile of the patients in this series presented a great deal of similarities with previously published ones (clinical presentation, burden of disease, age and response to treatment), with an average age of 66 years \[[@R1]--[@R10]\].

The classification of the cell of origin (COO) by IHC showed that 44% of the samples were GCB, and 33.3% non-GCB. We could not classified 16.6% of them. This results are similar to others series of PB-DLBCL \[[@R10], [@R15], [@R17]--[@R19]\]. The proliferation index, determined by Ki-67 expression, is strikingly high in these samples, higher than or equal to 80% in 16/18 samples. Previous publications of PBL described the Ki-67 index in a range between 70--90% \[[@R9],[@R10], [@R15], [@R18], [@R19]\].

The high frequency of *PIM1* mutations is one of the most relevant findings of this study. *PIM1* is a gene frequently targeted by aberrant somatic hypermutation \[[@R20]\], but many of the non-synonymous mutations identified in this study were located in the serine/threonine dual specificity protein kinase, catalytic domain (aa 38--290). One of these mutations (p.H68Y) has been previously reported to increase the activity of the enzyme, compared to the wild-type \[[@R20]\]. Others such as those in aa L184, L182, S146 and P125, previously described \[[@R21]\], have been shown not to affect the catalytic activity of the protein. The importance of *PIM1* in the development and evolution of hematologic malignancies, especially in lymphomas, has been known for many years \[[@R11], [@R22]--[@R23]\]. Our results show a higher frequency of mutations in PIM1 (50%) compared with other lymphomas of nodal (12--30%) \[[@R13]--[@R14]\] or extra-nodal origin (22--25%) \[[@R24]--[@R26]\], which may have implications in the clinical presentation and course of this type of lymphoma. Several studies have explored Pim kinases as a new target for pharmacological inhibition in cancer therapy, including multiple hematologic malignancies and suggest that PB-DLBCL could also benefit by this strategy as demonstrated previously \[[@R21], [@R27]--[@R29]\].

*MYD88* is the second most frequently mutated gene in this series. The seven mutated cases had the L265P mutation, which is the most recurrently found MYD88 mutation, it has been demonstrated to be an activating mutation leading to NFkB activation \[[@R30]--[@R33]\] and more frequently found in non-GCB DLBCL \[[@R34]--[@R35]\]. The four mutations found in CD79B were in exons 5 and 6 affecting the ITAM domain (aa 185--213). Two of them affected the tyrosine Y196 that was also demonstrated to be a gain-of-function mutation involved in the activation of the BCR- NFkB pathway \[[@R31]\]. Mutations in CARD11 affected the coiled coil and CARD (caspase recruitment) domains and mutations in these domains is a frequent event in DLBCL and have been shown also to activate NFkB in DLBCL cases \[[@R31], [@R36]--[@R39]\].

This is the first study describing a mutational profile of PBL. The study of Taniguchi *et al* \[[@R10]\] was the first to analyze *MYD88* and *CD79B* in a group of 48 patients with lymphomas of the breast. Twenty-eight of them met the diagnostic criteria for PB-DLBCL, according to the authors. Eighteen patients had systemic lymph node involvement or other extra-nodal sites (ovaries, central nervous system, bone marrow, and spleen). The frequencies of the mutations were 58% for *MYD88* and 33% for *CD79B*. These higher frequencies in Taniguchi series could be due to the highest sensitivity of the technique they used, digital polymerase chain reaction, and/or may reflect differences in the prevalence of etiological factors in Spanish and Japanese cohorts. Studies in others extra-nodal lymphomas, such as central nervous system and testis lymphomas, also showed *MYD88, CD79B* and *PIM1* as the most frequently mutated genes, and points out a common molecular profile for extra-nodal DLBCL \[[@R24]--[@R26]\]. Recently, a study described the mutational frequency of *MYD88* and *CD79B* in seven PB-DLBCL cases \[[@R17]\]. In this study 5 patients presented mutations in *MYD88* (L265P mutation in 4 cases and 1 case the L265S mutation) and 4 patients presented mutations in *CD79B* (Y196N, Y196H and Y196D). Only 2 of the 7 patients with PB-DLBCL showed mutations in both genes.

The most frequently mutated genes (PIM1, MYD88, CD79B, and CARD11) are more prevalent in non-GCB DLBCL as has been addressed in previous publications in both extra-nodal and nodal lymphomas \[[@R12], [@R39]--[@R41]\] (Figure [2](#F2){ref-type="fig"}). This point out to NFkB as the main pathway targeted for mutations in PB-DLBCL pathogenesis. Activating mutations in CD79B, CARD11 and MYD88 and inactivation mutations in TNFAIP3, leading to activation of NFkB pathway, constitute the hallmark of ABC-like DLBCL as has been reported in multiple publications \[[@R34], [@R35], [@R40]\]. This activation of NFkB is a characteristic mainly, although not exclusively, of ABC-DLBCL \[[@R13]--[@R14], [@R28]--[@R31], [@R38]\] (Figure [3](#F3){ref-type="fig"}). Mutations in other genes such as MLL2/KMT2D and CREBBP have been associated both to GCB and to non-GCB DLBCL \[[@R11], [@R12], [@R14], [@R34], [@R35], [@R41]\]. Although, in this series we did not see a clear association between the mutated genes with the COO determined by IHC, several previous studies show that COO classification, using the Hans method, only a variable percentage of cases showed concordance with gene expression profiling classification \[[@R42]\]. In fact, the pattern of mutations in PB-DLBCL seems to converge to NFkB activation, typical of the ABC phenotype. Finally, the presence of altered MYD88, CD79B and PIM1 suggests new therapeutic opportunities for PB-DLBCL using drugs like lenalidomide, BCR, NFkB or PIM inhibitors.

![Comparison of the distribution of recurrently mutated genes in DLBCL cohorts: The percentage of mutated cases for each gene represented were obtained from the following data: \*our data; \[[@R13], [@R14], [@R24]\]\
The distribution of mutations according to cell of origin (COO) in each series were represented when available. Grey: COO non-classified; green: non-GCB DLBCL, Blue: GCB DLBCL; purple: others](oncotarget-08-102888-g002){#F2}

![Schematic representation of the pathways affected in PB-DLBCL by mutations\
The most frequently mutated genes involved BCR and NFkB pathways and are more prevalent in non-GCB DLBCL. *Stars*: recurrently mutated genes in PB-DLBCL.](oncotarget-08-102888-g003){#F3}

MATERIALS AND METHODS {#s4}
=====================

Patients and samples {#s4_1}
--------------------

The study population consists of 17 patients, all women, with PB-DLBCL diagnosed between 1993 and 2016 in different medical centers in Spain. The research project was approved by the Ethics Committee of Puerta de Hierro University Hospital (Majadahonda, Spain) and conducted in accordance with the Declaration of Helsinki. Samples and clinical data were collected, processed and stored according to quality protocols, ensuring the safety and confidentiality of donors' data. The collected data included sex, age, tumor stage, laterality, treatment, relapse, PFS and OS (Table [1](#T1){ref-type="table"}). Clinical data were analyzed according to the modified criteria of Wiseman and Liao \[[@R4]--[@R5]\], and the histologic classification of the World Health Organization, 2008. We reviewed the biopsies in a single center to confirm the diagnosis; the COO was determined by IHC data using Hans algorithm.

Massive parallel sequencing {#s4_2}
---------------------------

We designed a targeted sequencing panel for aggressive B-cell lymphomas including 38 recurrently mutated genes described in the literature \[[@R11]--[@R14]\] ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

TruSeq^®^ Custom Amplicon Low Input Library for dual-strand sequencing (Illumina Inc. San Diego CA, USA) was used. Dual-strand sequencing eliminates false C-T mutations that can arise from deamination during formalin fixation. The probes for this custom panel were designed with DesignStudio (Illumina) and consisted of 1399 amplicons with an average size of 175 bp and a cumulative targeted region of 140 kb. Polymorphisms were avoided in the design of the primers.

DNA was extracted from formalin fixed and paraffin embedded tissues (FFPET) with truXTRACT FFPE DNA kit (Covaris, Woburn MA USA). Target enrichment was performed according to manufacturer's instructions. Total amount of input DNA per library ranged from 30 to 100 ng. After library preparation, indexing and bead purification, the libraries (two different libraries per sample, one per strand) were quantified by Qubit (Thermo Fisher Scientific, Waltham, MA, USA) and then normalized with beads and pooled for sequencing. The pooled libraries were sequenced with Miseq Reagent Kit V2 (paired-end, 2x150) on a MiSeq instrument (Illumina), as described in the manufacturer's protocol.

Median coverage for the amplicons for pool A was 379x (50--1098x) and pool B was 426x (30--2149x). For each sample alignment and variant calling was performed within MiSeq Reporter (Illumina) tool available in the instrument. Additionally, an independent variant calling was done with VarScan 2.4.0 \[[@R43]\] and annotation with Annovar \[[@R44]\]. All the variants identified by both complementary methods were visualized using IGV and only those mutations detected in both pool A and pool B were considered as valid. Data have been deposited in the Sequence Read Archive database (<http://www.ncbi.nlm.nih.gov/sra>) (SRP119626).
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